Cormorant Asset Management Has Decreased Sangamo Therapeutics (SGMO) Position By $1.60 Million; Inspired Entertainment (INSE) Shorts Down By 7.55%

September 26, 2017 - By Linda Rogers

Cormorant Asset Management Llc decreased Sangamo Therapeutics Inc (SGMO) stake by 33.33% reported in 2017Q2 SEC filing. Cormorant Asset Management Llc sold 200,000 shares as Sangamo Therapeutics Inc (SGMO)’s stock rose 95.00%. The Cormorant Asset Management Llc holds 400,000 shares with $3.52M value, down from 600,000 last quarter. Sangamo Therapeutics Inc now has $1.08 billion valuation. The stock decreased 4.44% or $0.6 during the last trading session, reaching $12.9. About 1.47 million shares traded. Sangamo Therapeutics Inc (NASDAQ:SGMO) has risen 29.78% since September 26, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.

Inspired Entertainment Incorporated (NASDAQ:INSE) had a decrease of 7.55% in short interest. INSE’s SI was 120,000 shares in September as released by FINRA. Its down 7.55% from 129,800 shares previously. With 12,100 avg volume, 10 days are for Inspired Entertainment Incorporated (NASDAQ:INSE)’s short sellers to cover INSE’s short positions. The SI to Inspired Entertainment Incorporated’s float is 4.16%. It closed at $13.4 lastly. It is down 0.00% since September 26, 2016 and is . It has underperformed by 16.70% the S&P500.

Inspired Entertainment, Inc., formerly Hydra Industries Acquisition Corp., is a global games technology company. The company has market cap of $300.03 million. The Firm is engaged in developing and operating digital games and networks. It currently has negative earnings. The Firm is engaged in supplying Virtual Sports, Mobile Gaming and Server-Based Gaming systems with associated terminals and digital content to regulated betting, gaming and lottery operators around the world.

Since May 11, 2017, it had 0 insider buys, and 2 insider sales for $34,754 activity. On Thursday, May 11 the insider Herberts Curt A. III sold $21,154.

Among 9 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 4 have Buy rating, 1 Sell and 4 Hold. Therefore 44% are positive. Sangamo Biosciences had 16 analyst reports since August 8, 2015 according to SRatingsIntel. The stock has “Hold” rating by Piper Jaffray on Thursday, August 10. The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) has “Sell” rating given on Tuesday, September 8 by Zacks. The rating was downgraded by Piper Jaffray to “Neutral” on Wednesday, October 19. As per Thursday, September 3, the company rating was maintained by JP Morgan. Cowen & Co maintained the shares of SGMO in report on Friday, September 4 with “Buy” rating. As per Thursday, August 4, the company rating was downgraded by Janney Capital. On Saturday, August 8 the stock rating was maintained by JP Morgan with “Overweight”. Wedbush maintained the stock with “Buy” rating in Wednesday, September 2 report. Jefferies maintained it with “Buy” rating and $18.0 target in Tuesday, September 12 report. Jefferies reinitiated the shares of SGMO in report on Friday, October 23 with “Buy” rating.

Investors sentiment increased to 1.59 in 2017 Q2. Its up 0.79, from 0.8 in 2017Q1. It increased, as 13 investors sold SGMO shares while 31 reduced holdings. 33 funds opened positions while 37 raised stakes. 50.83 million shares or 24.82% more from 40.72 million shares in 2017Q1 were reported. Point72 Asset Mngmt Ltd Partnership holds 0.02% or 357,705 shares. Hanson Mcclain holds 0% or 1,000 shares in its portfolio. Public Employees Retirement Association Of Colorado reported 0% stake. Highlander Cap Management Lc accumulated 0.1% or 14,000 shares. Jpmorgan Chase holds 1,990 shares or 0% of its portfolio. Alliancebernstein LP has invested 0% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Metropolitan Life Co New York has 48,332 shares. Deerfield Management Company invested 0.51% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO). Franklin Street Advsr Nc has 56,500 shares. Sanctuary Wealth Advisors Limited Liability Com owns 0.01% invested in Sangamo Therapeutics Inc (NASDAQ:SGMO) for 1,001 shares. National Bank Of New York Mellon Corporation has 339,842 shares. Dafna Limited Liability Corporation has invested 1.41% in Sangamo Therapeutics Inc (NASDAQ:SGMO). Baker Bros Ltd Partnership accumulated 0.32% or 4.11 million shares. Tiaa Cref Mgmt Lc has invested 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO). Cubist Systematic Strategies Lc invested 0% of its portfolio in Sangamo Therapeutics Inc (NASDAQ:SGMO).

Analysts await Sangamo Therapeutics Inc (NASDAQ:SGMO) to report earnings on October, 25. They expect $-0.20 EPS, up 25.93% or $0.07 from last year’s $-0.27 per share. After $-0.17 actual EPS reported by Sangamo Therapeutics Inc for the previous quarter, Wall Street now forecasts 17.65% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.